☆ 4.4 Letter

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

HAEMATOLOGICA (2020)

Get Full Text
Add to Collection

Journal

HAEMATOLOGICA
Volume 105, Issue 1, Pages E26-E28

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2019.220012

Keywords

-

Categories

Hematology

Funding

  1. NCI-CTEP U01 Grant Program at MDACC
  2. Celgene
  3. Millennium/Takeda
  4. National Stem Cell Foundation

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.